Roivant Sciences Ltd.
batoclimab
thyroid eye disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for batoclimab in thyroid eye disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“On April 2, 2026, the Company issued a press release announcing a new Phase 2b/3 clinical program at Priovant for brepocitinib in lichen planopilaris.”